NCT05785442View on ClinicalTrials.gov

Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

June 28, 2024

Study Completion Date

June 28, 2024

Conditions
Community-acquired PneumoniaHospital-acquired Pneumonia
Interventions
DRUG

Anakinra Prefilled Syringe

Anakinra 100 mg administration subcutaneously once daily for 10 days (at least 4 days)

DRUG

Placebo

0.67 ml N/S 0.9% w/v administration subcutaneously once daily for 10 days (at least 4 days)

Trial Locations (5)

12462

"4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Medical School", Athens

Unknown

1st Department of Internal Medicine, General Hospital of Athens GENNIMATAS, Athens

1st Department of Internal Medicine, General Hospital of Eleusis THRIASIO, Athens

6th Department of Pulmonary Medicine, SOTIRIA General Hospital of Chest Diseases of Athens, Athens

3rd Department of Internal Medicine, General Hospital of Nikaia AGIOS PANTELEIMON, Nikaia

All Listed Sponsors
lead

Hellenic Institute for the Study of Sepsis

OTHER